GlassScriptPhysician profile
Cynthia N Schaeffer
NPI 1497757215
$3,132.78
in general payments reported to CMS, 2019-2025
22 companies · $458 in 2025
The $458 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $275 · 2021: $390 · 2022: $438 · 2023: $606 · 2024: $742 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $502.23 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $328.76 | 2019-2024 | Dyanavel Xr |
| Cranial Technologies, INC | $318.90 | 2019-2025 | Doc Band |
| Corium, LLC | $252.94 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $252.67 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Kaleo, INC. | $217.62 | 2019-2024 | Auvi-Q |
| Sanofi Pasteur INC. | $192.16 | 2019-2024 | |
| Pfizer INC. | $176.24 | 2019-2025 | |
| Adlon Therapeutics L.P. | $128.47 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $115.64 | 2024-2025 | Relexxii |
| Collegium Pharmaceutical, INC. | $103.19 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $103.15 | 2022-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Seqirus USA INC | $89.44 | 2021-2025 | Flucelvax |
| Alk-Abello, INC | $70.00 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals LP | $59.87 | 2022-2024 | Flumist Quadrivalent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $50.42 | 2021-2022 | |
| Hologic Sales and Service, LLC | $49.39 | 2024 | Aptima |
| Sobi, INC | $45.90 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $27.32 | 2024 | Qelbree |
| Qiagen, LLC | $18.52 | 2025 | |
| Phadia US INC. | $15.60 | 2023 | Immunocap |
| Aytu Biopharma, INC. | $14.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Schaeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.